Compound News and Research

RSS

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects.

16 Apr 2010

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

16 Apr 2010

European patent for XenoPort's investigational compound is valid

XenoPort, Inc. announced today that the European Patent Office (EPO) Opposition Division ruled that the European patent for the composition of matter of XP13512 (European Patent No. 1 404 324) is valid.

16 Apr 2010

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.

15 Apr 2010

Novel drug helps discover mechanisms underlying female sexual arousal

By using a novel prototype drug, researchers have discovered more about the mechanisms underlying female sexual arousal. These findings are published today in the British Journal of Pharmacology.

15 Apr 2010

Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting

Achillion Pharmaceuticals, Inc. today presented data from the Company's ongoing Phase 1 clinical trial of ACH-1625 to treat hepatitis C at the European Association for the Study of the Liver's International Liver Congress taking place at the Reed Messe Wien Congress Center in Vienna, Austria from April 14-18, 2010.

15 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

15 Apr 2010

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Avid Radiopharmaceuticals, Inc. today announced the presentation of interim data from its landmark florbetapir "Image-to-Autopsy" Phase III study. These data come from the first cohort of subjects in the trial and are the first ever Phase III results for an agent designed to image Alzheimer's disease pathology.

15 Apr 2010

PROP compound linked to obesity and risk of cardiovascular disease

Whether or not you can taste a bitter compound called 6-n-propylthiouracil (or PROP) may help Professor Beverly Tepper identify your risk for becoming obese and/or developing cardiovascular disease.

15 Apr 2010

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Restrictions should be placed on the use of Ginkgo biloba - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes. The article appears in ACS' monthly Journal of Natural Products.

15 Apr 2010

Drinking tap water is a cost-effective way to fight tooth decay

Tooth decay affects children in the United States more than any other chronic infectious disease, according to the Centers for Disease Control and Prevention (CDC). The CDC states that tooth decay, if left untreated, can cause pain and infections that hinder eating, speaking, playing and learning.

15 Apr 2010

Sigma Life Science announces latest version of 'Your Favorite Gene Powered By Ingenuity' research portal

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich®, today announced a significant expansion to its web-based biological research portal for exploring dynamic gene-based content, Your Favorite Gene Powered By Ingenuity (http://www.wherebiobegins.com/yfg).

13 Apr 2010

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Myriad Pharmaceuticals, Inc today announced that it has received a notice from Javelin Pharmaceuticals, Inc. of its intent to terminate the merger agreement between the two companies.

13 Apr 2010

Researchers may be one step closer to slowing the progression of Alzheimer's disease

Researchers may be one step closer to slowing the onset and progression of Alzheimer's disease. An animal study supported by the National Institute of Environmental Health Sciences, part of the National Institutes of Health, shows that by targeting the blood-brain barrier, researchers are able to slow the accumulation of a protein associated with the progression of the illness.

13 Apr 2010

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

13 Apr 2010

Compound that kills specific lymphoma cells discovered

An international research team co-led by the Ontario Cancer Institute has discovered a compound that kills specific lymphoma cells - a discovery that will accelerate developing targeted drugs to fight the most common form of non-Hodgkins lymphoma.

13 Apr 2010

DHA crucial for male fertility

According to a University of Illinois study, omega-3 fatty acids may be good for more than heart health. A little-known omega-3 may have implications for treating male infertility.

13 Apr 2010

Elastomers speed regulatory compliance of speech therapy devices, enhance toughness

A supplier of tools to aid in speech therapy has switched from conventional thermoplastic elastomers to Medalist® medical elastomers from Teknor Apex Company, citing advantages in compound selection, blending, molding, and resistance to chewing and other rugged treatment.

12 Apr 2010

Compound News and Research

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

European patent for XenoPort's investigational compound is valid

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Novel drug helps discover mechanisms underlying female sexual arousal

Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

PROP compound linked to obesity and risk of cardiovascular disease

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Drinking tap water is a cost-effective way to fight tooth decay

Sigma Life Science announces latest version of 'Your Favorite Gene Powered By Ingenuity' research portal

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Researchers may be one step closer to slowing the progression of Alzheimer's disease

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Compound that kills specific lymphoma cells discovered

DHA crucial for male fertility

Elastomers speed regulatory compliance of speech therapy devices, enhance toughness

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News